A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
Phase 4
Completed
NCT05341115
| Condition | Central Precocious Puberty |
|---|
| Phase | Phase 4 |
|---|
| Sponsor | Takeda |
|---|
| Status | Completed |
|---|
| Enrollment | 79 participants |
|---|
| Interventions | Leuprorelin Acetate Depot 3M |
|---|
| Start date | Mar 12, 2023 |
|---|
| Completion date | Dec 19, 2024 |
|---|
| Results posted | Jan 13, 2026 |
|---|
Summary
The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study clinic 6 times to complete some assessments.
Percentage of Participants With Peak Luteinizing Hormone (LH) Suppression in Gonadotropin-Releasing Hormone (GnRH) Stimulation at Week 24
Week 24 · percentage of participants
| Leuprorelin Acetate Depot 3M 11.25 mg | 96.20 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.